This study is for young people aged 13 to 20 who are having a kidney transplant. It compares two different combinations of medicines used after transplant to prevent the body from rejecting the new kidney. One group will receive belatacept and sirolimus, while the other will receive tacrolimus and Mycophenolate Mofetil (MMF). Researchers want to see if one combination is safer and more effective at preventing problems like the body making antibodies against the new kidney or a decline in kidney function. You would need to have had a past infection with Epstein-Barr virus (EBV) to join. The study plans to enroll 200 participants and will follow them for 12 to 24 months after their transplant.

Study design

This is an interventional study where 200 participants will be randomly assigned to one of two treatment groups after their kidney transplant.

What's involved

Participants will receive specific immunosuppressant medications (sirolimus, belatacept, Mycophenolate Mofetil, tacrolimus, Anti-Thymocyte Globulin) according to their assigned group for up to 24 months. The study duration from transplant to the primary endpoint is 12-24 months.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 12 to 24 months after their transplant, with the primary endpoints measured at 96 weeks post-transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.